Avalo Therapeutics CMO sells 679 shares
Avalo Therapeutics, Inc.’s Chief Medical Officer, Doyle Mittie, reported an exercise-and-sell stock transaction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Avalo Therapeutics, Inc.’s Chief Medical Officer, Doyle Mittie, reported an exercise-and-sell stock transaction. On May 28, 2026, she exercised stock options to acquire 679 shares of common stock at $8.04 per share and sold 679 shares in an open-market trade at $16.00 per share.
The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2025. Following these trades, she directly holds 47,122 shares of common stock and 118,321 stock options that remain outstanding.
Insider Trade Summary 10b5-1
Exercise and Sale: 679 shares ($5K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Doyle Mittie
Role
Chief Medical Officer
Sold
679 shs ($11K)
Approx. gross sale proceeds
$11K
Approx. exercise cost
$5K
Approx. pre-tax spread
$5K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 679 | $0.00 | $0.00 |
| Exercise | Common Stock | 679 | $8.04 | $5K |
| Sale | Common Stock | 679 | $16.00 | $11K |
Holdings After Transaction:
Stock Option (Right to Buy) — 118,321 contracts (Direct);
Common Stock — 47,122 shares (Direct)
Footnotes (2)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
- F2. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Shares sold: 679 shares
Sale price: $16.00 per share
Option exercise price: $8.04 per share
+4 more
7 metrics
Shares sold
679 shares
Common Stock sold on May 28, 2026 in open market
Sale price
$16.00 per share
Price for 679 common shares sold on May 28, 2026
Option exercise price
$8.04 per share
Exercise price for 679 shares from stock option
Shares after transaction
47,122 shares
Common Stock directly owned following May 28, 2026 trades
Options remaining
118,321 options
Stock options outstanding after the reported exercise
Option expiration
January 28, 2035
Expiration date of the exercised stock option series
Net share change
-679 shares
Net of buys and sells according to transaction summary
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy), Chief Medical Officer, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
Chief Medical Officer financial
"officer_title": "Chief Medical Officer""
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Exercise or conversion of derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Avalo Therapeutics (AVTX) report for Doyle Mittie?
Avalo Therapeutics reported that Chief Medical Officer Doyle Mittie exercised stock options and sold shares. On May 28, 2026, she exercised options for 679 common shares and sold 679 shares in an open-market transaction, as disclosed in a Form 4 insider trading report.
What stock option exercise did Avalo Therapeutics (AVTX) disclose for Doyle Mittie?
Doyle Mittie exercised stock options covering 679 shares at $8.04 per share. The options were described as a Stock Option (Right to Buy), and the exercise took place on May 28, 2026 as part of the transactions reported in the Form 4.
Were Doyle Mittie’s Avalo Therapeutics (AVTX) transactions under a Rule 10b5-1 plan?
Yes, the Form 4 states the transactions were made under a Rule 10b5-1 trading plan. The plan was adopted on November 13, 2025, indicating the May 28, 2026 exercise and sale were pre-arranged rather than discretionary trades.
AI-generated analysis. How Rhea-AI works. Not financial advice.
